Grant: CIHR Fellowship
Direct Payment
$100,000.00
Identification of a novel immunosuppressive FcRn ligand: implications for cancer .
FY 2014-15
Summary
Cancers are characterized by abnormal cell growth that can spread to other parts of the organism. An important mechanism the body has evolved to keep those abnormal cells in check is their recognition and elimination by the immune system. Nevertheless, cancers are often able to avoid immune recognition through secretion of factors that can block normal immune functions. One of the suspect molecules is alpha-fetoprotien (AFP), a protein normally present in great quantities during fetal life, and abnormally produced in adults by a fraction of liver, testicular or ovarian cancer cells. Although AFP has been ascribed with several functions either beneficial during fetal period or detrimental during adulthood, how exactly it does so is not known since the receptor to which it binds to achieve its functions has not been identified. We have discovered that this receptor is neonatal Fc receptor (FcRn) and propose studies to verify whether AFP binding to FcRn is responsible for the ability of certain cancers to escape immune recognition. If this is the case, by blocking FcRn-AFP interactions, as we propose to examine, can be used therapeutically to increase the recognition and thus the elimination of cancer cells.
Department
Program
CIHR Fellowship
Recipient
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
318856
Name
Pyzik Michal
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Identification of a novel immunosuppressive FcRn ligand: implications for cancer .
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Antigen Presentation; Cancer Immunology; Fluorescence-Activated Cell Sorting; Humanized Mouse Models; Immunotherapy; Receptor Signalling; Receptor-Ligand Interaction; Site Directed Mutagenesis; Surface Plasmon Resonance
Abstract
Cancers are characterized by abnormal cell growth that can spread to other parts of the organism. An important mechanism the body has evolved to keep those abnormal cells in check is their recognition and elimination by the immune system. Nevertheless, cancers are often able to avoid immune recognition through secretion of factors that can block normal immune functions. One of the suspect molecules is alpha-fetoprotien (AFP), a protein normally present in great quantities during fetal life, and abnormally produced in adults by a fraction of liver, testicular or ovarian cancer cells. Although AFP has been ascribed with several functions either beneficial during fetal period or detrimental during adulthood, how exactly it does so is not known since the receptor to which it binds to achieve its functions has not been identified. We have discovered that this receptor is neonatal Fc receptor (FcRn) and propose studies to verify whether AFP binding to FcRn is responsible for the ability of certain cancers to escape immune recognition. If this is the case, by blocking FcRn-AFP interactions, as we propose to examine, can be used therapeutically to increase the recognition and thus the elimination of cancer cells.
Competitiondate
201411
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Pyzik, Michal
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~